Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab pegol plus methotrexate in active rheumatoid arthritis with incomplete methotrexate response
2005-002326-63Phase 3Completed
- Sponsor
- UCB
- Start
- Aug 2005
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of certolizumab pegol in rheumatoid arthritis (RA) (3 arms), sponsored by UCB. Primary endpoints: Efficacy in signs and symptoms of rheumatoid arthritis, Prevention of joint damage and 1 more. Started Aug 2005; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-002326-63.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002326-63.